Message #11 From:
Stock News Bot Date: January 8, 2007 04:00:00 AM
PKTX News ProtoKinetix Highlights AAGP(TM) Development and Production Strategy
VANCOUVER, British Columbia--(BUSINESS WIRE)--ProtoKinetix Inc. (OTCBB: PKTX) summarizes the highlights of the
scientific accomplishments attained over the last 24 months to develop a
commercially viable group of products. The first hurdle was to determine
that the AAGPTM molecule was stable and lacked
toxicity. Upon these confirmations, PKTX concentrated on human cell
preservation at various temperatures. Early studies showed a greater
than 300% increase in cell preservation down to -20 oC.
Efficacy test results showed a 98% red blood cell preservation after
being subjected to -15 oC for 9 hrs as opposed
to 100% mortality for cells not treated. Further tests showed a
significant reduction of platelet aggregation from 22 oC
to 0 oC. Scientists at the University of Rouen
expanded the family of AAGPTM molecules and
found them to be stable and safe. A third party laboratory found that
AAGPTM increased heart cell and heart tissue
survivability. AAGP™ was shown to slow the
aging process of human skin cells at temperatures ranging from 37o
C (core body temperature) down to 0o C.
More intense stress to human skin cells using H2O2
and UV-C resulted in successful preservation when treated with AAGPTM.World wide patents and subsequent extensions were then filed.
After laying the above scientific foundations, in 2006 ProtoKinetix
began to concentrate on trials that were targeted toward specific
markets. At the request of a cosmetic corporation, the Company conducted
trials using very low concentrations of AAGPTM.
The results showed minimal decline in the preservative effects attained.
Again, targeting the cosmetic market, PKTX showed that AAGPTM
proves to be a powerful additive compared to coenzymeQ10
and side by side. Third party testing showed that lengthy exposure to
AAGPTM maintained cell integrity and function
even with high concentrations of the molecule (15 mg/ml).
Patent expansions included AAGPTM molecules
ranging from the very smallest (320 daltons) single amino acid based
molecule through to the largest (2.2 kilodaltons) AAGPTM
molecule that would have any practical application.
INSA (Francès National Institute of Applied
Science) chose AAGPTM as its project to present
at the annual GECO Conference. ProtoKinetix’
lead scientist was awarded the prestigious Francinov Award for the
development of the AAGPTM family of molecules.
Recent studies have shown that AAGPTM
significantly reduces inflammation. This new development has opened up
several avenues for research and business development. The latest UV
exposure experiments suggest that AAGPTM not
only protects cells from UV light but may also be acting at a molecular
level to induce the repair of damaged cells. A new market for AAGPTM
has been opened up by the discovery that the addition of this molecule
to a solution of DMSO in cryopreservation of cell lines increased the
thawed out cell viability by 100%.
Capitalizing on the significant scientific breakthroughs accomplished
over the last few months, ProtoKinetix has a wide range of choices for
maximizing the commercial value of the Company. PKTX’
focus for 2007 is to launch AAGPTM into the
markets which require no regulatory approval to a fast track approval.
These markets include:
1. Skin care applications – anti-aging and
anti-oxidant additives for cosmetic use
2. Sun protection agents – protection and
repair
3. Cryopreservation of cells and tissues
4. Preservation of organs, islets and skin cells for transplantation
In anticipation of successful contractual negotiations in the first
quarter of this year, ProtoKinetix has entered into discussion with
major chemical corporations to dramatically ramp up the production of
the AAGPTM family of molecules. As of this
date, PKTX has entered into 6 specific application development
agreements with major universities, institutions and corporations. These
developments will very quickly establish the market value of AAGPTM
which will ultimately determine the long term value of the Company.
About ProtoKinetix:
ProtoKinetix Inc. is a Biotechnical Company dedicated to the development
of a family of synthetic antifreeze glycoproteins (AAGP™)
for human and veterinary medicine, the biotechnology and cosmetic
industries, and as a food additive. Using previously published research
on native antifreeze proteins and antifreeze glycoproteins as a guide,
and coordinating a vast pool of world recognized intellectual talent in
a networked environment, PKTX is conducting rapid and meaningful
research with a view to developing markets for this very useful family
of molecules. Sign up for free automatic email news alerts at our new
website at: www.protokinetix.com
Statements contained herein that are not historical facts may be
forward-looking statements within the meaning of the Securities Act of
1933, as amended. Forward-looking statements include statements
regarding the intent, belief or current expectations of the Company and
its management. Such statements are estimates only, as the Company has
not completed the preparation of its financial statements for those
periods, nor has its auditor completed the audit of those results. Such
statements reflect management's current views, are based on certain
assumptions and involve risks and uncertainties. Actual results, events,
or performance may differ materially from the above forward-looking
statements due to a number of important factors, and will be dependent
upon a variety of factors, including, but not limited to PKTX's ability
to obtain additional financing, to obtain regulatory approvals in a
timely manner, and the demand for PKTX's products. PKTX undertakes no
obligation to publicly update these forward-looking statements to
reflect events or circumstances that occur after the date hereof or to
reflect any change in PKTX's expectations with regard to these
forward-looking statements or the occurrence of unanticipated events.
Factors that may impact PKTX's success are more fully disclosed in
PKTX's most recent public filings with the U.S. Securities and Exchange
Commission.
